We tested the hypothesis that the mechanism of action of the antifolate dru
g trimethoprim is through accumulation of bacterial dihydrofolate resulting
in depletion of tetrahydrofolate coenzymes required for purine and pyrimid
ine biosynthesis. The folate pool of a strain of Escherichia coli (NCIMB 88
79) was prelabeled with the folate biosynthetic precursor [H-3]-p-aminobenz
oic acid before treatment with trimethoprim. Folates in untreated E. coli w
ere present as tetrahydrofolate coenzymes. In trimethoprim-treated cells, h
owever, a rapid transient accumulation of dihydrofolate occurred, followed
by complete conversion of all forms of folate to cleaved catabolites (pteri
dines and para-aminobenzoylglutamate) and the stable nonreduced form of the
vitamin, folic acid. Both para-aminobenzoylglutamate and folic acid were p
resent in the cell in the form of polyglutamates. Removal of trimethoprim r
esulted in the reconversion of the accumulated folic acid to tetrahydrofola
te cofactors for subsequent participation in the one-carbon cycle. Whereas
irreversible catabolism is probably bactericidal, conversion to folic acid
may constitute a bacteriostatic mechanism since, as we show, folic acid can
be used by the bacteria and proliferation is resumed once trimethoprim is
removed. Thus, the clinical effectiveness of this important drug may depend
on the extent to which the processes of either catabolism or folic acid pr
oduction occur in different bacteria or during different therapeutic regime
s.